WuXi Biologics has received EMA GMP certificates for the production of Trogarzo at its cGMP Drug Substance and Drug Product manufacturing facilities in Wuxi city and its cGMP cell banking facilities in Shanghai. Trogarzo, an HIV treatment, is developed by TaiMed Biologics and marketed in the U.S. and EU by Theratechnologies.   “This marks yet another great milestone that WuXi Biologics has achieved and lays a solid foundation for us to significantly expand our manufacturing capacity and ...